Physician profile
Manuela Berry
NPI 1063070308
$4,044.31
in general payments reported to CMS, 2019-2025
30 companies · $382 in 2025
The $382 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,096 · 2022: $1,262 · 2023: $660 · 2024: $645 · 2025: $382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,686.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,686.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,532.00 | 2021-2025 | |
| Novo Nordisk INC | $528.44 | 2021-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $276.55 | 2021-2024 | Farxiga, Breztri |
| Merck Sharp & Dohme LLC | $202.74 | 2021-2024 | Vaxneuvance, Gardasil, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $166.53 | 2022-2024 | |
| Glaxosmithkline, LLC. | $162.74 | 2021-2025 | Arexvy, Shingrix, Blujepa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.85 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Avanir Pharmaceuticals, INC. | $135.76 | 2021-2022 | |
| Lilly USA, LLC | $113.70 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $89.92 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $84.85 | 2022-2024 | Caplyta |
| Novartis Pharmaceuticals Corporation | $80.09 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $72.97 | 2023-2025 | Gemtesa |
| Ironwood Pharmaceuticals, INC | $62.21 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $60.27 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $38.53 | 2022 | |
| Pfizer INC. | $29.95 | 2021-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $29.52 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.22 | 2022-2024 | Xifaxan |
| Supernus Pharmaceuticals, INC. | $25.54 | 2021 | |
| Impel Pharmaceuticals INC. | $25.00 | 2022 | |
| Si-Bone, INC. | $24.10 | 2024 | |
| Almatica Pharma LLC | $19.56 | 2023 | Sertraline Hcl, Gralise, Loreev Xr |
| Currax Pharmaceuticals LLC | $17.36 | 2024 | Contrave |
| Sanofi-Aventis U.S. LLC | $16.56 | 2022 | |
| Nestle Healthcare Nutrition INC. | $16.11 | 2023 | |
| Vanda Pharmaceuticals INC. | $14.21 | 2023 | Hetlioz, Fanapt |
| Evoke Pharma, INC. | $12.09 | 2021 | |
| Esperion Therapeutics, INC. | $12.02 | 2021 | |
| Astellas Pharma US INC | $9.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manuela Berry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.